Frequently Asked Questions

Divesiran works by temporarily silencing the production of the TMPRSS6 protein found in liver cells, which in turn increases the body’s production of another protein called hepcidin. By increasing hepcidin levels, divesiran aims to redirect iron delivery away from the bone marrow, lowering red blood cell production and potentially reducing the high red blood cell count in people living with PV. This may reduce the need for phlebotomies and lower the risk of blood clots and strokes. In addition, PV related symptoms such as fatigue, brain fog, and itchy skin may be reduced.

Divesiran is injected under the skin. Patients will be seen every 6 weeks to receive treatment, have their health evaluated and their response to treatment. Assessments take up to 4 hours each visit.

Results from the phase 1 portion of the SANRECO study showed that divesiran was well tolerated without dose-limiting toxicities. Treatment emergent adverse events were recorded in 19/21 participants, with 84% of TEAEs grade 1. There were no treatment-related serious adverse events or TEAEs leading to discontinuation¹.

The phase 1 portion of the SANRECO study is now complete. Additionally, data will be presented at medical meetings throughout 2025.

The phase 2 portion of the SANRECO study has completed enrolling patients and is now ongoing to evaluate divesiran in the treatment of polycythemia vera (PV).